9 results about "Blood level" patented technology

An electronic device comprises a housing configured to contact a user's skin, an optical transmitter array, an optical receiver, a memory element and a processing element. The optical transmitter array outputs a plurality of optical signals that pass through the user's skin, each of the plurality of optical signals having one of three wavelengths. The optical receiver receives the optical signals and generates corresponding photoplethysmogram (PPG) signals. The memory element stores absorption constants for deoxyhemoglobin blood content, oxyhemoglobin blood content and glycated hemoglobin blood content, each absorption constant associated with one of the first wavelength, the second wavelength or the third wavelength. The processing element determines a glycated hemoglobin blood level for the user based on a ratio of a determined glycated hemoglobin blood content to a sum of determined deoxyhemoglobin blood content, a determined oxyhemoglobin blood content and a determined glycated hemoglobin blood content.

Provided in the present application are an autologous blood reinfusion system and method. The system comprises a collection module, a storage module, an output module, and a control module, wherein the collection module is configured to collect blood from a target subject and transfer the blood to the storage module; the storage module is configured to store the blood and acquire a blood level height value; the output module comprises a first driving unit, a filtering unit, and a first pressure monitoring unit, the first driving unit being configured to deliver the blood in the storage module to the filtering unit, the filtering unit being configured to filter the blood and deliver the filtered blood to the target subject, and the first pressure monitoring unit being configured to acquire a first pressure value of the filtering unit; and the control module is configured to compare the blood level height value with a first threshold, and send a stop signal to the first driving unit when the blood level height value is less than the first threshold, and is further configured to compare the first pressure value with a second threshold, and send a stop signal to the first driving unit when the first pressure value is greater than the second threshold.

The present invention relates to agglomerates of soluble whey protein aggregates for use in the treatment and / or prevention of one or more conditions linked to GLP-1 blood levels in a human subject.

To provide a suitable means for delivering a therapeutic biomolecule to a patient, wherein a stable and therapeutically effective blood level of the biomolecule occurs in a stable and convenient form over an extended period of time.SOLUTION: Provided is a device for treating a disease in a subject, wherein the subject may have Crohn's disease, ulcerative colitis, primary sclerosing cholangitis, eosinophilic esophagitis, autoimmune hepatitis, the device comprising a cell chamber comprising a population of cells that secrete a biomolecule for delivery to the subject.SELECTED DRAWING: None

Provided is a computer-implemented method for selecting a subject at risk for developing Crohn's disease, including a trained logistic regression model classifying a subject as at risk for developing Crohn's disease based on blood levels of C-X-C motif chemokine ligand (9), transforming growth factor α, hepatocyte growth factor, C-C motif chemokine ligand (11), matrix metalloproteinase (10), matrix metalloproteinase (1), C-X-C motif chemokine ligand (11), C-C motif chemokine ligand (19), C-C motif chemokine ligand (23), and tumor necrosis factor β.

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sEng antibody bound to a solid support in order to reduce blood levels of sEng. The present invention provides a method of treating or preventing a disorder associated with soluble Endoglin (sEng), such as a pregnancy-related hypertensive disorder, in a subject in need thereof comprising providing ex vivo to the subject anti-sEng antibodies or sEng-binding fragments thereof in an amount sufficient and for a time sufficient to decrease the subject's blood levels of sEng to treat or prevent the disorder associated with sEng in the subject.

This application relates to a vascular artificial embolism formation and control system. The system includes an embolism pressure control component, a gas pipeline, a liquid level adjustment component, and a liquid pipeline. The embolism pressure control component controls the gas pressure and volume of the artificial embolism; the liquid level adjustment component includes a liquid extraction control element and a liquid collection container, used to adjust the blood level in the blood vessel after the artificial embolism at the required pressure is formed, thereby controlling the position of the artificial embolism within the blood vessel. This control system can precisely control the gas pressure, gas volume, and position of the artificial embolism in the blood vessel, overcoming the problem of blood backflow during the retrograde movement of the artificial embolism, and significantly reducing the risk of the artificial embolism entering the circulatory system through collateral circulation, effectively preventing the possibility of gas embolism causing harm to other parts of the body; it also reduces the consumption of artificial embolism gas and the loss of blood from the patient during the procedure.

The present disclosure provides a combination of a liposomal suspension, and of albumin, for use as bile acid sequestrants, wherein the use comprises (a) intraperitoneally administering the liposomal suspension to a subject in need thereof; and (b) intravenously or intraperitoneally administering the albumin to the subject; and (c) removing a dialysate containing liposomes and at least one bile acid from the subject, wherein the at least one bile acid comprises cholic acid, glycocholic acid, glycochenodeoxycholic acid or a combination of at least two thereof.

A paper-based analytical device for potentiometric assay of Arylsulfatase A (ARSA) activity levels. The analytical device comprises a filter paper substrate supporting a potentiometric cell, a reference electrode, and an ion-selective electrode. The electrodes are constructed using an ink comprising carbon nanotubes and reduced graphene oxide (r-GO). The analytical device also includes a solid-contact potentiometric sensor for ARSA integrated with the electrodes and a polymeric membrane associated with the ion-selective electrode. The analytical device is capable of providing results from actual serum and whole blood samples. A method for monitoring blood ARSA levels and a method for fabricating the analytical device are also disclosed.